FDA to Review Merck’s COVID-19 Vaxx: Bloomberg

Published on October 14, 2021

The U.S. Food and Drug Administration (FDA) will send drug maker Merck & Co.’s experimental COVID-19 antiviral drug to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.

Read Full Article (External Site)